Here are the latest updates on the approval and upcoming sales of Presvu Eye Drops:
- Government Approval: The Drug Controller General of India (DCGI) has approved Presvu Eye Drops, developed by Entod Pharmaceuticals.
- Vision Improvement: These eye drops can improve vision within 15 minutes of application.
- Sales Launch: Presvu Eye Drops will be available for sale starting next month.
- Target Condition: The eye drops are designed to treat presbyopia, a common age-related vision problem.
- Market Impact: This approval marks a significant advancement in eye care innovation in India.
- Usage Benefits: Presvu Eye Drops aim to reduce the reliance on reading glasses for individuals with presbyopia.
- Product Availability: The eye drops will be launched in the domestic market in the first week of October.
- Global Reach: Entod Pharmaceuticals plans to expand the product to emerging markets such as Africa and Southeast Asia.
- Cost: The eye drops will be available at a cost of Rs 350 per bottle.
- Expert Opinion: Dr. Aditya Sethi highlighted that Presvu Eye Drops can significantly improve near vision, enhancing the quality of life for many.
-
The “Shadow Bank” Loophole is Closed: Why Your NBFC Loan Just Became a Bank Loan in Disguise
Your NBFC loan is now a “Bank trap” in disguise. The RBI’s silent “Twin-Trigger” rule means one mistake
-
Bank of Maharashtra Breaks the Floor: Why 7.10% May Be the Lowest You’ll See
7.10% isn’t just a rate cut—it’s a “wealth trap” for the unaware. BoM’s aggressive slash hides a secret
-
The 18-Month Trap: Why the New US Work Permit Rule is a Silent Crisis for Indians in 2025
It’s not just a filing fee—it’s a trap. USCIS just slashed work permits to 18 months, but the
-
The Invisible Doctor in Your Hospital Room Just Got Fired: What the ₹50,000 Star Health Verdict Really Means for You
Your “Cashless” card has a secret enemy. A court just fined Star Health for playing “Invisible Doctor,” but
-
Advance Tax 2025: Why the Taxman Might Charge You 1% Interest While You Sleep
The December 15 tax deadline isn’t just for business owners. Over 40% of salaried employees face a hidden
-
The Safe Bet Just Changed the Game: What LIC’s Two New 2025 Schemes Are Really Hiding
The “safe” bet just got dangerous. LIC’s new Bima Kavach quietly locks out millions with a shocking ₹2





